Hims & Hers Sees 16% Upside with $32 Price Target on Peptides
HIMS•Hims & Hers received a maintained $32 price target from Canaccord Genuity, implying a 16% upside as shares aim for a two-week winning streak. The firm highlighted peptides as a multi-year growth driver following Hims’s 2025 acquisition of a California manufacturing facility and in-house lab testing capabilities.
1. Analyst Rating and Price Target
Canaccord Genuity reiterated its Buy rating on Hims & Hers and upheld a $32 price target, signaling a 16% potential rise from current levels. Shares have climbed 5% this week and are targeting a second consecutive weekly gain, reflecting growing investor confidence.
2. Peptides as Long-Term Growth Driver
The brokerage sees compounded peptides as a key multi-year opportunity, as ongoing FDA reviews could shift demand from unregulated channels into mainstream healthcare. Success in this category could expand Hims’s preventive health, longevity and wellness offerings.
3. Manufacturing and Testing Infrastructure
In early 2025, Hims acquired a California peptide manufacturing facility to secure domestic supply and foster innovation. The company also added in-house lab testing, enhancing its vertically integrated platform for future peptide therapies.
